Standout Papers

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): ... 2016 2026 2019 2022 344
  1. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials (2016)
    Nicola A. Hanania, Phillip E. Korenblat et al. The Lancet Respiratory Medicine

Immediate Impact

1 from Science/Nature 58 standout
Sub-graph 1 of 22

Citing Papers

Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy
2024 Standout
Interstitial Lung Disease
2024 Standout
2 intermediate papers

Works of Charles Asare being referenced

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
2016 Standout

Author Peers

Author Last Decade Papers Cites
Charles Asare 147 54 17 293 220 4 490
Renata Martincova 168 80 39 185 186 8 434
A.J. Frew 44 30 1 362 161 8 533
Ashraf Uzzaman 94 55 12 211 151 9 506
G. Hense 24 21 8 235 342 6 564
Chris Kell 33 53 2 292 154 7 415
Hirohita Kita 81 115 4 437 209 7 521
Shih‐Ying Wu 81 51 9 117 150 9 416
Dylan Birchard 53 92 11 272 154 4 433
Jeanne Allinne 53 91 11 268 153 5 430
Barry P. Sandall 16 37 24 155 224 6 486

All Works

Loading papers...

Rankless by CCL
2026